clinical trial · NCT07383025
Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan
Bristol-Myers Squibb·—·recruiting·n = 200
Obstructive Hypertrophic Cardiomyopathy (oHCM)Mavacamten
brief summary
The purpose of this study is to assess the real-world effectiveness and safety of mavacamten in patients with obstructive hypertrophic cardiomyopathy (HCM) receiving mavacamten in Japan
started
May 21, 2025
primary completion
Nov 30, 2029
completion
Nov 30, 2029
last updated
Feb 3, 2026
official title
Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy (oHCM) in Japan
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol